| Document |
Document Title |
|
WO/2024/062076A1 |
The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to human CCR8 and is an antagonist, particularly an insurmountable antagonist, of the CCL1-CCR8 signaling pathway. Th...
|
|
WO/2024/064002A1 |
OKI-179 alone or in combination with a MAPK pathway inhibitor is described for the treatment of a cancer resulting from one or more mutations in the MAPK pathway.
|
|
WO/2024/064358A1 |
This disclosure features chemical entities (e.g., a compound of Formula (I), (I-a), (I-b), or (I-c), or a pharmaceutically acceptable salt thereof) that induce degradation of Stimulator of Interferon Genes (STING). Said chemical entities...
|
|
WO/2024/064756A1 |
Disclosed are bispecific modulators. Bispecific modulators can bind to a protein of interest and to an internalizing receptor on a cell surface. Once bound, the protein of interest can be internalized and/or degraded inside a cell.
|
|
WO/2024/062047A1 |
The present invention relates generally to the field of anti-cancer therapy, in particular to the use of agents or co-agents useful in anti-cancer immunotherapy such as adoptive T-cell transfer (ACT) immunotherapy and immune check-point ...
|
|
WO/2024/064724A1 |
This invention relates to methods of treating cancer, enhancing an immune response and/or reducing and/or reversing immunosuppression to cancer in a subject having, suspected to have and/or at risk of cancer. The invention further relate...
|
|
WO/2024/061345A1 |
The present application belongs to the field of medicines, and provides an HPK1 inhibitor, a preparation method therefor, and use thereof. Particularly, disclosed are a compound of formula (I'), a preparation method therefor, a pharmaceu...
|
|
WO/2024/064690A1 |
Disclosed herein are polymorph forms of (S)-N-(2-amino-l-(3-chloro-5-fluorophenyl)ethyl)-l-(5- methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-lH
-imidazole-4-carboxamide, L- mandelic acid salt:
|
|
WO/2024/061343A1 |
The present disclosure relates to a PKMYT1 inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound or the pharmaceut...
|
|
WO/2024/061213A1 |
The present invention provides a carbonyl fused heterocyclic derivative used as a ubiquitin-specific protease inhibitor, and specifically relates to a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptab...
|
|
WO/2024/059909A1 |
The invention relates to antigen binding proteins and related fragments thereof for binding to CCR8, to production of said antigen binding proteins and fragments and to use of said antigen binding proteins and fragments for detection and...
|
|
WO/2024/059908A1 |
Processes for the synthesis of [89Zr]ZrCl4 from [89Zr][Zr(oxalate)4]4- salt are provided. The [89Zr]ZrCl4 can be reacted with biomarker targeting agents to produce 89Zr labelled radiopharmaceuticals. The 89Zr labelled radiopharmaceutical...
|
|
WO/2024/063576A1 |
The present invention relates to a novel quinazoline compound as a KRAS inhibitor and, more specifically, to a novel quinazoline compound useful as a KRAS protein inhibitor, an isomer, and a pharmaceutical composition for cancer treatmen...
|
|
WO/2024/061203A1 |
Provided herein are a pharmaceutical composition containing a therapeutically effective amount of furmonertinib or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, and use of furmonertinib ...
|
|
WO/2024/064316A1 |
Described herein are compounds and conjugates of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 inhibitors or degraders).
|
|
WO/2024/061267A1 |
A pharmaceutical composition, and a preparation method therefor and the use thereof. The pharmaceutical composition contains: (4aR,8R)-3-acryloyl-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-
8-(2-isopropyl-4-methylpyridin-3-yl)-6-methyl-2,3,...
|
|
WO/2024/064233A1 |
A near-infrared imaging agent includes a targeting peptide that specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed b...
|
|
WO/2024/064878A1 |
Disclosed herein are methods of treating melanoma, such as, e.g., stage III/IV cutaneous or mucosal melanoma, in a subject in need thereof, comprising administering a therapeutically effective amount of denosumab to the subject and optio...
|
|
WO/2024/064769A1 |
The disclosure relates, in some aspects, to methods and compositions for production of immunogenic compositions. In some embodiments, the disclosure provides T cells which have been treated ex vivo with one or more oligonucleotide agents...
|
|
WO/2024/062073A1 |
VISTA antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, composition comprising, and methods using, the VISTA antigen-binding molecules.
|
|
WO/2024/060948A1 |
The present invention relates to a T cell receptor (TCR) specifically binding to a human papillomavirus E7, a nucleic acid encoding the TCR, an engineered cell comprising same, and a method for preparing the engineered cell. The present ...
|
|
WO/2024/064958A1 |
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cu...
|
|
WO/2024/063545A1 |
The present invention relates to a composition comprising a Lactobacillus plantarum strain for improving intestinal metabolite composition. The Lactobacillus plantarum strain according to one embodiment can reduce intestinal polyamines (...
|
|
WO/2024/064783A1 |
This disclosure relates to compositions and methods to enhance therapeutic efficacy of cancer therapies.
|
|
WO/2024/064713A1 |
The disclosure provides antibodies or antigen-binding domains thereof specific for CD228 and fusion proteins specific for both CD137 and CD228, which fusion proteins can be used to co-stimulate lymphocyte activation in a CD228-target-dep...
|
|
WO/2024/060966A1 |
The present invention relates to a pan-KRAS inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inflam...
|
|
WO/2024/063670A1 |
The present invention relates to novel compounds of formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, which exhibit the properties of a CDK7 inhibitor, as well as to a pharmaceutical composition containin...
|
|
WO/2024/062250A1 |
The present invention relates to compounds of Formula (I) that may act as inhibitors of checkpoint kinase 1 (Chk1). The invention also relates to pharmaceutical compositions comprising those compounds, and to their use in the treatment o...
|
|
WO/2024/064310A2 |
|
|
WO/2024/061350A1 |
Provided is a fusion protein consisting of SIRPαV2 and a CD3 antibody.
|
|
WO/2024/060577A1 |
The present invention relates to an armored CAR-T cell expressing interleukin 15 receptor α and interleukin 15 and immunotherapeutic use thereof.
|
|
WO/2024/062113A1 |
The present invention relates to a method for producing or identifying one or several shared cancer epitope(s), as well as peptides comprising or consisting of the epitopes identified or produced by said method, expression vectors encodi...
|
|
WO/2024/063648A1 |
The present invention is directed to a scaffold and a compound for targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts (CAFs). The scaffold comprises a (4-quinoinolyl)glycinyl-2-cyanopyrrolidine scaffold that i...
|
|
WO/2024/062023A1 |
A Neem tree leaf extract of the present invention is enriched in Nimbolide and/or depleted in Azadirachtin content compared to the relative average proportional content of these components in Neem tree leaves. A method for producing such...
|
|
WO/2024/061298A1 |
The present invention relates to a heterocyclo-substituted methanone derivative and the use thereof. In particular, the present invention provides a solid form of (S)-(3-amino-5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperid
in]-1'-yl)pyr...
|
|
WO/2024/061118A1 |
The present invention provides a macrocyclic nitrogen-containing crown ether compound represented by formula (I) and use thereof as a protein kinase inhibitor.
|
|
WO/2024/064080A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2024/060422A1 |
Disclosed are a double-targeting CAR-T cell targeting mesothelin and an NKG2D ligand and use thereof, and particularly disclosed is a chimeric antigen receptor, which comprises a nanobody targeting mesothelin and a protein targeting an N...
|
|
WO/2024/064968A1 |
The present disclosure relates to the field of fibroblast activation protein (FAP) inhibitors, conjugates comprising the novel FAP inhibitors, including radiotracers, for the imaging, diagnosis and treatment of conditions characterized b...
|
|
WO/2024/064754A1 |
Disclosed are bispecific modulators that include a therapeutic agent. Embodiments include bispecific modulators conjugated to therapeutic agents. Bispecific modulators can bind to a protein of interest and to an internalizing receptor on...
|
|
WO/2024/062319A1 |
Conjugates of biologically active compounds are disclosed. The compounds can have the following structure (I): Formula (I) or a stereoisomer, tautomer, or salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, L1a, L1b, L2, L3, L4, L5, L6, L7...
|
|
WO/2024/059901A1 |
The invention is directed to compositions and methods for preventing or rescuing exhaustion of immune effector cells, especially CAR T cells. The compositions and methods comprise bispecific polypeptides with a first antigen binding prot...
|
|
WO/2024/061333A1 |
Provided are a compound of formula I having KRas inhibitory activity, a pharmaceutical composition comprising the compound, a preparation method therefor, and use thereof. The compound has remarkable selectivity, inhibitory activity, and...
|
|
WO/2024/061211A1 |
Provided are a lipid compound for nucleic acid delivery, and related use and a medicament comprising same. Particularly, provided are use of a lipid compound comprising one or more compounds represented by the following formula (I) in pr...
|
|
WO/2024/064288A1 |
The present disclosure relates to methods and compositions useful for treating cancer in a subject in need thereof. Said methods and compositions comprising inhibitors of toll-like receptor 4 (TLR4) signaling.
|
|
WO/2024/063188A1 |
The present specification provides plasma-activated water containing about 2 ppm or more of dissolved hydrogen and microbubbles, and a composition comprising same.
|
|
WO/2024/064969A2 |
The present disclosure relates to the field of nuclear imaging and therapy, and more specifically to high purity copper radiotracer compositions useful in imaging, such as positron emission tomography (PET) and single-photon emission com...
|
|
WO/2024/061554A1 |
A PARP7 inhibitor compound comprises formula (I), X1 is selected from C, and N. R1, R2, and R3, are each independently H or an organic group. R9 is H or an organic group, or is absent when X1 is N. L is (II). Each R4 is independently sel...
|
|
WO/2024/062019A1 |
The present invention relates to antibodies specific for the chemokine (C-C motif) receptor 8 (CCR8). The present invention further relates to the use of these antibodies for depleting CCR8-expressing tumor regulatory T cells, and to pre...
|
|
WO/2024/064721A2 |
The present disclosure is concerned with methods of treating disorders associated with overexpression of an eyes absent (EYA) protein such as, for example, vascular disease, a fibrosis-related disorder, hearing loss, and a metabolic dise...
|
